193 related articles for article (PubMed ID: 15264993)
1. Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia.
Petrides PE
Expert Opin Pharmacother; 2004 Aug; 5(8):1781-98. PubMed ID: 15264993
[TBL] [Abstract][Full Text] [Related]
2. Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment.
Prescrire Int; 2006 Jun; 15(83):83-6. PubMed ID: 16764090
[TBL] [Abstract][Full Text] [Related]
3. Anagrelide: what was new in 2004 and 2005?
Petrides PE
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):399-408. PubMed ID: 16810615
[TBL] [Abstract][Full Text] [Related]
4. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
Iványi JL; Marton É; Plander M; Szendrei T
Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
[TBL] [Abstract][Full Text] [Related]
5. Anagrelide: a review of its use in the management of essential thrombocythaemia.
Wagstaff AJ; Keating GM
Drugs; 2006; 66(1):111-31. PubMed ID: 16398570
[TBL] [Abstract][Full Text] [Related]
6. [Primary thrombocythemia: diagnosis and therapy].
Petrides PE
Med Klin (Munich); 2006 Aug; 101(8):624-34. PubMed ID: 16896569
[TBL] [Abstract][Full Text] [Related]
7. [Anagrelide in the treatment of thrombocythemia essential (ET)].
Mazur G; Wróbel T; Podolak-Dawidziak M; Kuliszkiewicz-Janus M; Potoczek S; Nosol J; Kuliczkowski K
Pol Arch Med Wewn; 2004 Dec; 112(6):1445-50. PubMed ID: 15962609
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia.
Gotic M; Egyed M; Gercheva L; Warzocha K; Kvasnicka HM; Achenbach H; Wu J
Cardiovasc Toxicol; 2021 Mar; 21(3):236-247. PubMed ID: 33123978
[TBL] [Abstract][Full Text] [Related]
9. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany.
Petrides PE; Beykirch MK; Trapp OM
Eur J Haematol; 1998 Aug; 61(2):71-6. PubMed ID: 9714517
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
[TBL] [Abstract][Full Text] [Related]
11. Anagrelide, a selective thrombocytopenic agent.
Oertel MD
Am J Health Syst Pharm; 1998 Oct; 55(19):1979-86. PubMed ID: 9784784
[TBL] [Abstract][Full Text] [Related]
12. Treatment of essential thrombocythemia in childhood.
Scherer S; Ferrari R; Rister M
Pediatr Hematol Oncol; 2003; 20(5):361-5. PubMed ID: 12775533
[TBL] [Abstract][Full Text] [Related]
13. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
Cacciola RR; Di Francesco E; Pezzella F; Tibullo D; Giustolisi R; Cacciola E
Acta Haematol; 2007; 118(4):215-8. PubMed ID: 18057866
[No Abstract] [Full Text] [Related]
14. [Anagrelide in primary thrombocythemia].
Knutsen H; Hysing J
Tidsskr Nor Laegeforen; 2001 May; 121(12):1478-82. PubMed ID: 11449771
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of anagrelide in treatment of essential thrombocythemia: multicenter, randomized controlled clinical trial].
Ge X; Yang L; Jin J; Qian W; Li J; Yang R; Cao X; Jiang B; Wang Z; Hou M; Zhang W; Xiao Z; Zhao Y; Gao D; Zhang X; Wang S; Sun A; Fu J; Su L; Li K
Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):547-52. PubMed ID: 26304075
[TBL] [Abstract][Full Text] [Related]
16. Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia.
Spencer CM; Brogden RN
Drugs; 1994 May; 47(5):809-22. PubMed ID: 7520859
[TBL] [Abstract][Full Text] [Related]
17. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.
Gisslinger H; Gotic M; Holowiecki J; Penka M; Thiele J; Kvasnicka HM; Kralovics R; Petrides PE;
Blood; 2013 Mar; 121(10):1720-8. PubMed ID: 23315161
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.
Ito T; Hashimoto Y; Tanaka Y; Nakaya A; Fujita S; Satake A; Nakanishi T; Konishi A; Hotta M; Yoshimura H; Ishii K; Hashimoto A; Kondo T; Omura H; Shinzato I; Tanaka T; Nomura S
Eur J Haematol; 2019 Aug; 103(2):116-123. PubMed ID: 31107982
[TBL] [Abstract][Full Text] [Related]
19. A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trial.
Gisslinger H; Buxhofer-Ausch V; Hodisch J; Radinoff A; Karyagina E; Kyrcz-Krzemień S; Abdulkadyrov K; Gerbutavicius R; Melikyan A; Burgstaller S; Hus M; Kłoczko J; Yablokova V; Tzvetkov N; Całbecka M; Shneyder T; Warzocha K; Jurgutis M; Kaplanov K; Jilma B; Schoergenhofer C; Klade C
Br J Haematol; 2019 May; 185(4):691-700. PubMed ID: 30919941
[TBL] [Abstract][Full Text] [Related]
20. Indications for lowering platelet numbers in essential thrombocythemia.
Barbui T
Semin Hematol; 2003 Jan; 40(1 Suppl 1):22-5. PubMed ID: 12682878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
